Paul Chapman

Paul Chapman at Memorial Sloan Kettering led the landmark BRIM-3 phase III trial establishing vemurafenib as the first targeted therapy for BRAF V600E-mutated melanoma, achieving unprecedented response rates and transforming melanoma treatment. His translational research on BRAF inhibitor mechanisms, resistance pathways, and optimal combination strategies has been foundational for the field. He demonstrated the dramatic clinical responses possible with BRAF inhibitors in a tumor type that had minimal effective systemic therapy. His continuing research on BRAF/MEK inhibitor combinations and approaches to prevent or overcome resistance has advanced melanoma targeted therapy.